Literature DB >> 22986349

Early and delayed tranilast treatment reduces pathological fibrosis following myocardial infarction.

Fiona See1, Masataka Watanabe2, Andrew R Kompa1, Bing H Wang1, Andrew J Boyle3, Darren J Kelly3, Richard E Gilbert4, Henry Krum1.   

Abstract

BACKGROUND: Tranilast has been shown to inhibit TGFβ1-related fibrosis and organ failure in various disease models. We sought to examine the effects of tranilast on left ventricular (LV) remodelling post-MI.
METHODS: Following coronary artery ligation, Sprague Dawley rats were randomised to receive tranilast (300mg/kg/d, p.o.) or vehicle control over one of two treatment periods: (1) from 24h until seven days post-MI, (2) from seven days to 28 days post-MI. Cardiac tissue was harvested for molecular, immunohistochemical and cell culture analyses.
RESULTS: Tranilast treatment of MI rats from 24h until seven days post-MI reduced myocardial collagen content, α1 (I) procollagen, TGFβ1 and CTGF mRNA transcripts, monocyte/macrophage infiltration and exacerbated infarct expansion compared with vehicle-treatment. Delaying the commencement of tranilast treatment to seven days post-MI attenuated myocardial fibrosis, gene expression of α1(I) procollagen, α1(III) procollagen, fibronectin, TGFβ1 and CTGF mRNA transcripts, and monocyte/macrophage infiltration at 28d compared to vehicle-treatment, without detriment to infarct healing. Extended post-MI also preserved LV infarct size. In cultures of rat cardiac fibroblasts, tranilast attenuated TGFβ1-stimulated fibrogenesis.
CONCLUSION: Tranilast inhibits myocardial TGFβ1 expression, fibrosis in rat post-MI and collagen production in cardiac fibroblasts. While tranilast intervention from 24h post-MI exacerbated infarct expansion, delaying the commencement of treatment to seven days post-MI impeded LV remodelling.
Copyright © 2012 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22986349     DOI: 10.1016/j.hlc.2012.08.054

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  13 in total

Review 1.  Cardiac fibrosis: potential therapeutic targets.

Authors:  Shuin Park; Ngoc B Nguyen; Arash Pezhouman; Reza Ardehali
Journal:  Transl Res       Date:  2019-03-09       Impact factor: 7.012

Review 2.  Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature.

Authors:  Feby Savira; Ruth Magaye; Danny Liew; Christopher Reid; Darren J Kelly; Andrew R Kompa; S Jeson Sangaralingham; John C Burnett; David Kaye; Bing H Wang
Journal:  Br J Pharmacol       Date:  2020-05-13       Impact factor: 8.739

Review 3.  The NLRP3 Inflammasome as a Novel Therapeutic Target for Cardiac Fibrosis.

Authors:  Jiwen Fan; Meng Ren; Binay Kumar Adhikari; Haodong Wang; Yuquan He
Journal:  J Inflamm Res       Date:  2022-07-07

4.  Tranilast binds to aβ monomers and promotes aβ fibrillation.

Authors:  Christopher R Connors; David J Rosenman; Dahabada H J Lopes; Shivina Mittal; Gal Bitan; Mirco Sorci; Georges Belfort; Angel Garcia; Chunyu Wang
Journal:  Biochemistry       Date:  2013-05-31       Impact factor: 3.162

5.  Ataxia telangiectasia-mutated kinase deficiency exacerbates left ventricular dysfunction and remodeling late after myocardial infarction.

Authors:  Laura L Daniel; Stephanie L C Scofield; Patsy Thrasher; Suman Dalal; Christopher R Daniels; Cerrone R Foster; Mahipal Singh; Krishna Singh
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-06-10       Impact factor: 4.733

6.  Deficiency of ataxia telangiectasia mutated kinase delays inflammatory response in the heart following myocardial infarction.

Authors:  Laura L Daniel; Christopher R Daniels; Saghar Harirforoosh; Cerrone R Foster; Mahipal Singh; Krishna Singh
Journal:  J Am Heart Assoc       Date:  2014-12       Impact factor: 5.501

7.  Late onset oral treatment with tranilast following large myocardial infarction has no beneficial effects on cardiac remodeling and mortality in rats.

Authors:  Stefan Betge; Christian Kunz; Hans Figulla; Christian Jung
Journal:  Exp Ther Med       Date:  2014-10-06       Impact factor: 2.447

8.  Importance of human peritoneal mesothelial cells in the progression, fibrosis, and control of gastric cancer: inhibition of growth and fibrosis by tranilast.

Authors:  Hiroto Saito; Sachio Fushida; Shinichi Harada; Tomoharu Miyashita; Katsunobu Oyama; Takahisa Yamaguchi; Tomoya Tsukada; Jun Kinoshita; Hidehiro Tajima; Itasu Ninomiya; Tetsuo Ohta
Journal:  Gastric Cancer       Date:  2017-05-24       Impact factor: 7.370

Review 9.  Transforming growth factor β: A potential biomarker and therapeutic target of ventricular remodeling.

Authors:  Yuan Ma; Hai Zou; Xing-Xing Zhu; Jie Pang; Qiang Xu; Qin-Yang Jin; Ya-Hui Ding; Bing Zhou; Dong-Sheng Huang
Journal:  Oncotarget       Date:  2017-04-19

Review 10.  Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling.

Authors:  Warisara Parichatikanond; Theerut Luangmonkong; Supachoke Mangmool; Hitoshi Kurose
Journal:  Front Cardiovasc Med       Date:  2020-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.